High-risk corneal allografts

A therapeutic challenge

Tian Yu, Vijayalakshmi Rajendran, May Griffith, John V Forrester, Lucia Kuffová

Research output: Contribution to journalArticle

5 Downloads (Pure)

Abstract

Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.

Original languageEnglish
Pages (from-to)10-27
Number of pages18
Journal World Journal of Transplantation
Volume6
Issue number1
Early online date3 Dec 2015
DOIs
Publication statusPublished - 24 Mar 2016

Fingerprint

Allografts
Transplants
Cornea
Therapeutics
Regenerative Medicine
Corneal Transplantation
Graft Rejection
Adaptive Immunity
Graft Survival
Antigen-Presenting Cells
Blindness
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Innate Immunity
Immunosuppression
Homeostasis
Survival Rate
Tissue Donors
Inflammation
Technology

Keywords

  • "high-risk" grafts
  • graft rejection
  • systemic immunosuppression
  • cell-based immunomodulation
  • keratoprosthesis
  • collagen-based hydrogels

Cite this

High-risk corneal allografts : A therapeutic challenge. / Yu, Tian; Rajendran, Vijayalakshmi; Griffith, May; Forrester, John V; Kuffová, Lucia.

In: World Journal of Transplantation, Vol. 6, No. 1, 24.03.2016, p. 10-27.

Research output: Contribution to journalArticle

Yu, Tian ; Rajendran, Vijayalakshmi ; Griffith, May ; Forrester, John V ; Kuffová, Lucia. / High-risk corneal allografts : A therapeutic challenge. In: World Journal of Transplantation. 2016 ; Vol. 6, No. 1. pp. 10-27.
@article{d6ebc26008524c5abf90f624a3172072,
title = "High-risk corneal allografts: A therapeutic challenge",
abstract = "Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86{\%} at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in {"}low-risk{"} settings. Furthermore, although corneal graft survival in {"}low-risk{"} recipients is favourable, the prognosis in {"}high-risk{"} recipients for corneal graft is poor. In {"}high-risk{"} grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of {"}high-risk{"} recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in {"}high-risk{"} recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both {"}low-risk{"} and {"}high-risk{"} hosts.",
keywords = "{"}high-risk{"} grafts, graft rejection, systemic immunosuppression, cell-based immunomodulation, keratoprosthesis, collagen-based hydrogels",
author = "Tian Yu and Vijayalakshmi Rajendran and May Griffith and Forrester, {John V} and Lucia Kuffov{\'a}",
year = "2016",
month = "3",
day = "24",
doi = "10.5500/wjt.v6.i1.10",
language = "English",
volume = "6",
pages = "10--27",
journal = "World Journal of Transplantation",
issn = "2220-3230",
publisher = "Baishideng Publishing Group",
number = "1",

}

TY - JOUR

T1 - High-risk corneal allografts

T2 - A therapeutic challenge

AU - Yu, Tian

AU - Rajendran, Vijayalakshmi

AU - Griffith, May

AU - Forrester, John V

AU - Kuffová, Lucia

PY - 2016/3/24

Y1 - 2016/3/24

N2 - Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.

AB - Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.

KW - "high-risk" grafts

KW - graft rejection

KW - systemic immunosuppression

KW - cell-based immunomodulation

KW - keratoprosthesis

KW - collagen-based hydrogels

U2 - 10.5500/wjt.v6.i1.10

DO - 10.5500/wjt.v6.i1.10

M3 - Article

VL - 6

SP - 10

EP - 27

JO - World Journal of Transplantation

JF - World Journal of Transplantation

SN - 2220-3230

IS - 1

ER -